SCM
Silverarc Capital Management Portfolio holdings
AUM
$489M
This Quarter Return
+2.21%
1 Year Return
+71.55%
3 Year Return
+1,109.63%
5 Year Return
–
10 Year Return
–
AUM
$223M
AUM Growth
+$223M
(-23%)
Cap. Flow
-$41.8M
Cap. Flow
% of AUM
-18.79%
Top 10 Holdings %
Top 10 Hldgs %
38.27%
Holding
101
New
18
Increased
23
Reduced
24
Closed
32
Top Buys
| 1 |
Merus
MRUS
|
$7.25M |
| 2 |
89bio
ETNB
|
$6.67M |
| 3 |
Viking Therapeutics
VKTX
|
$6.33M |
| 4 |
Karyopharm Therapeutics
KPTI
|
$6M |
| 5 |
KalVista Pharmaceuticals
KALV
|
$5.69M |
Top Sells
| 1 |
MORF
Morphic Holding, Inc. Common Stock
MORF
|
$10.6M |
| 2 |
Madrigal Pharmaceuticals
MDGL
|
$9.67M |
| 3 |
Immunovant
IMVT
|
$9.22M |
| 4 |
Xenon Pharmaceuticals
XENE
|
$5.62M |
| 5 |
BLU
BELLUS Health Inc.
BLU
|
$5.09M |
Sector Composition
| 1 | Healthcare | 95.65% |
| 2 | Technology | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Biogen
BIIB
$20.8B
| $3.14M | 1.3% |
11,311
-10,664
| -49% | -$2.96M |
|
27
Celldex Therapeutics
CLDX
$1.57B
| $3.05M | 1.26% |
84,651
+29,952
| +55% | +$1.08M |
|
28
Alnylam Pharmaceuticals
ALNY
$58.6B
| $2.81M | 1.16% |
14,043
-23,609
| -63% | -$4.73M |
|
29
Krystal Biotech
KRYS
$4.35B
| $2.72M | 1.12% |
34,014
-24,521
| -42% | -$1.96M |
|
30
Cullinan Oncology
CGEM
$456M
| $2.71M | 1.12% |
265,032
+35,616
| +16% | +$364K |
|
31
Pliant Therapeutics
PLRX
$105M
| $2.66M | 1.1% |
100,000
-117,503
| -54% | -$3.13M |
|
32
Mirum Pharmaceuticals
MIRM
$3.75B
| $2.54M | 1.05% |
+105,939
| New | +$2.54M |
|
33
Incyte
INCY
$17B
| $2.45M | 1.01% |
+33,938
| New | +$2.45M |
|
34
Insmed
INSM
$30.3B
| $2.45M | 1.01% |
143,794
+19,329
| +16% | +$330K |
|
35
Protagonist Therapeutics
PTGX
$3.62B
| $2.43M | 1% |
+105,486
| New | +$2.43M |
|
|
36
Madrigal Pharmaceuticals
MDGL
$9.7B
| $2.42M | 1% |
10,000
-39,898
| -80% | -$9.67M |
|
37
Ventyx Biosciences
VTYX
$184M
| $2.35M | 0.97% |
+70,000
| New | +$2.35M |
|
38
MoonLake Immunotherapeutics
MLTX
$3.78B
| $2.26M | 0.93% |
+105,750
| New | +$2.26M |
|
39
Mersana Therapeutics
MRSN
$34.8M
| $2.22M | 0.92% |
540,059
-600,123
| -53% | -$2.47M |
|
40
Immatics
IMTX
$662M
| $1.95M | 0.8% |
282,432
-157,356
| -36% | -$1.09M |
|
|
MORF
41
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $1.95M | 0.8% |
51,684
-282,851
| -85% | -$10.6M |
|
42
Aclaris Therapeutics
ACRS
$223M
| $1.78M | 0.74% |
220,100
-132,093
| -38% | -$1.07M |
|
43
Trevi Therapeutics
TRVI
$871M
| $1.64M | 0.68% |
885,924
+118,293
| +15% | +$219K |
|
|
RXDX
44
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
| $1.49M | 0.62% |
13,921
-36,079
| -72% | -$3.87M |
|
|
PNT
45
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
| $1.44M | 0.6% |
198,477
-202,335
| -50% | -$1.47M |
|
46
Phathom Pharmaceuticals
PHAT
$843M
| $1.43M | 0.59% |
+200,000
| New | +$1.43M |
|
47
Intellia Therapeutics
NTLA
$1.26B
| $1.41M | 0.58% |
37,858
+5,088
| +16% | +$190K |
|
|
CLYM
48
Climb Bio, Inc. Common Stock
CLYM
$165M
| $1.41M | 0.58% |
485,955
+76,753
| +19% | +$223K |
|
49
Seres Therapeutics
MCRB
$162M
| $1.32M | 0.54% |
232,525
-141,897
| -38% | -$805K |
|
50
Sarepta Therapeutics
SRPT
$1.98B
| $1.28M | 0.53% |
+9,270
| New | +$1.28M |
|